Letrozole

FDA Approved

Aromatase Inhibitor | Potent Estrogen Suppression

Weight: 285.30 Da
Half-life: ~2 days (48 hours)
5 studies
2015 latest
FDA Approved
Dose 0.25-0.5mg EOD (on-cycle); 2.5mg/day (medical)
Frequency Every other day (cycle support); daily (breast cancer / fertility)
Cycle Short-term rescue use preferred; duration of aromatizable compound use if ongoing
Storage Room temperature (20-25C), protected from light and moisture
Accumulation Plotter

Community Research

Join others researching Letrozole — share findings, ask questions, and learn from real experiences

View Results Aggregated community findings
Discussion Questions & experiences
Submit Your Findings Contribute your research data

Letrozole is the most potent of the three commonly used aromatase inhibitors (letrozole > anastrozole > exemestane), capable of suppressing circulating estradiol by approximately 98% at the standard medical dose of 2.5mg daily. It is FDA-approved under the brand name Femara for the treatment of hormone receptor-positive breast cancer in postmenopausal women and is also used off-label for ovulation induction in fertility medicine. In the bodybuilding and hormone optimization context, letrozole is often considered the "nuclear option" among AIs -- reserved for severe gynecomastia flare-ups, very high aromatizing cycles, or situations where anastrozole has proven insufficient. Its extreme potency is a double-edged sword: while it is highly effective at controlling estrogen, it is also very easy to crash estrogen to undetectable levels, which produces debilitating side effects including severe joint pain, profound fatigue, mood disturbance, and impaired sexual function. Most experienced users treat letrozole as a rescue compound rather than a first-line estrogen management tool, reaching for it only when other options have failed or when rapid, aggressive estrogen suppression is genuinely necessary.

Mechanism of Action

Letrozole competitively and reversibly binds to the heme group of the aromatase enzyme (cytochrome P450 19A1), inhibiting its catalytic activity with greater potency than any other commercially available aromatase inhibitor. Aromatase catalyzes the final step in estrogen biosynthesis, converting testosterone to estradiol and androstenedione to estrone in peripheral tissues including adipose, muscle, liver, and brain. At the standard 2.5mg daily dose, letrozole achieves greater than 99% aromatase inhibition in vivo, reducing circulating estradiol by approximately 98%. Even at lower doses used in bodybuilding protocols (0.25-0.5mg every other day), letrozole produces substantial estrogen suppression that exceeds what anastrozole achieves at standard doses. The inhibition is reversible, meaning estrogen production resumes after the drug is cleared, though the approximately 2-day half-life means recovery takes several days after discontinuation. Because estrogen plays critical physiological roles in men -- including bone metabolism, lipid homeostasis, neurocognition, joint lubrication, and cardiovascular protection -- the overwhelming potency of letrozole demands careful, conservative dosing and regular bloodwork monitoring.

01 Most potent aromatase inhibitor available, achieving ~98% estradiol suppression at medical doses
02 Effective rescue compound for acute gynecomastia flare-ups unresponsive to other AIs
03 Capable of managing estrogen on very high aromatizing cycles where anastrozole is insufficient
04 Oral dosing with a 2-day half-life supports every-other-day scheduling
05 Well-characterized pharmacokinetics with extensive clinical data from breast cancer treatment
06 Reversible inhibition allows estrogen recovery after discontinuation
07 FDA-approved with decades of safety and efficacy data

Molecular Data

Molecular Weight
285.30 Da
Type
Nonsteroidal aromatase inhibitor (triazole derivative)
Peak 0.0 mcg
Trough 0.0 mcg
SS Peak 0.0 mcg
SS Trough 0.0 mcg

Research Indications

On-Cycle Estrogen Management
Severe Gynecomastia Intervention most effective

Used as a rescue compound when gynecomastia is actively progressing despite other interventions. Letrozole's extreme potency can rapidly suppress the estrogen driving breast tissue growth. Typically used short-term at low doses until the flare subsides, then transitioned to a milder AI or SERM for maintenance.

High-Dose Aromatizing Cycles effective

On cycles involving high doses of testosterone or other heavily aromatizing compounds (e.g., testosterone above 750mg/week, or stacked with Dianabol), estrogen production may exceed what anastrozole can manage. Letrozole at conservative doses (0.25mg EOD) can provide the additional suppression needed.

Estrogen Crash Risk Management effective

The primary challenge with letrozole is avoiding excessive estrogen suppression. Even small dose adjustments can dramatically impact estradiol levels. Requires frequent bloodwork and careful titration -- starting at the lowest effective dose and increasing only if confirmed necessary by labs.

Medical Applications
Breast Cancer Treatment (Postmenopausal Women) most effective

FDA-approved as adjuvant therapy and extended adjuvant therapy for hormone receptor-positive breast cancer in postmenopausal women. The BIG 1-98 trial demonstrated superior disease-free survival compared to tamoxifen, establishing letrozole as a first-line AI in oncology.

Ovulation Induction (Off-Label) most effective

Widely used off-label as a first-line treatment for ovulation induction in women with polycystic ovary syndrome (PCOS) or unexplained infertility. Letrozole has shown superior live birth rates compared to clomiphene citrate in multiple clinical trials.

Hormonal Optimization
Refractory Estrogen Elevation effective

For individuals who aromatize heavily due to genetics, high body fat, or supraphysiological androgen doses, and who do not achieve adequate estrogen control with anastrozole. Letrozole at micro-doses may provide the potency needed, but the margin of error is slim.

Temporary Estrogen Suppression effective

Short-term use to rapidly bring estradiol into range before transitioning to a less potent AI for ongoing management. This approach uses letrozole's strength while minimizing the risks of prolonged exposure.

Dosing Protocols

Letrozole is administered orally as a tablet, with approximately 99.9% bioavailability -- essentially complete absorption. Food does not significantly affect absorption. The 2-day half-life supports every-other-day dosing for estrogen management protocols, though bodybuilding doses are dramatically lower than the medical 2.5mg/day breast cancer dose. Tablets are commonly available in 2.5mg strength and can be split or quartered for the lower doses typically used in hormonal optimization.

GoalDoseFrequencyRoute
On-cycle estrogen management (conservative)0.25mgEvery other day (EOD)Oral
On-cycle estrogen management (moderate)0.5mgEvery other day (EOD)Oral
Gynecomastia flare-up (short-term rescue)0.5-1mgEvery other day (EOD) for 1-2 weeks, then taperOral
Breast cancer treatment (medical)2.5mgOnce dailyOral

Interactions

++
Testosterone (exogenous)
Letrozole is used alongside exogenous testosterone to suppress estrogen on high-aromatizing cycles. Due to its extreme potency, it is typically reserved for situations where anastrozole is insufficient. Start at the lowest dose (0.25mg EOD) and titrate based on bloodwork. The goal is estrogen modulation, not elimination -- crashed estrogen is as harmful as excess estrogen.
synergistic
!
Anastrozole (Arimidex)
Both are aromatase inhibitors with overlapping mechanisms. Combining two AIs provides no therapeutic advantage and dramatically increases the risk of crashing estrogen to undetectable levels. Choose one or the other based on the degree of estrogen suppression needed. Letrozole is appropriate when anastrozole alone is insufficient; it is not meant to be stacked with it.
avoid
~
Tamoxifen (Nolvadex)
Tamoxifen and letrozole act through different mechanisms -- tamoxifen blocks estrogen at the receptor while letrozole suppresses estrogen synthesis. Clinical data from the BIG 1-98 breast cancer trial suggests sequential use (one followed by the other) is effective, but concurrent use requires caution. Tamoxifen may interfere with letrozole's pharmacokinetics. If both are used, monitor estradiol levels and clinical response closely.
monitor
!
Exemestane (Aromasin)
Both are aromatase inhibitors. Exemestane is a steroidal, irreversible (suicidal) inhibitor while letrozole is nonsteroidal and reversible, but combining them serves no purpose and massively increases the risk of estrogen depletion. Use one AI only.
avoid
~
HCG
HCG stimulates intratesticular aromatase activity directly, producing estradiol independently of peripheral aromatization. This can partially counteract letrozole's systemic aromatase inhibition. When combining HCG with letrozole, be aware that estradiol levels may be less suppressed than expected, and dose adjustments may be needed. Monitor bloodwork.
monitor

What to Expect

Day 1-2
Letrozole begins inhibiting aromatase within hours of ingestion. Due to its high potency, estradiol levels start declining rapidly. No noticeable symptomatic effects yet.
Day 3-7
Significant estradiol suppression is underway. Water retention and bloating may begin to decrease. Approaching steady-state plasma concentrations (reached in approximately 2-6 weeks at daily dosing, faster at the pharmacological level with EOD dosing). Some users notice early joint stiffness if the dose is too aggressive.
Week 1-2
Substantial estrogen suppression achieved. Gynecomastia progression should halt. Water weight continues to drop. If estrogen is crashed, symptoms become apparent rapidly: severe joint pain and stiffness, extreme fatigue, flat or depressed mood, loss of libido, and dry skin. Bloodwork at this stage is critical.
Week 2-4+
Full steady-state pharmacological effect. Ongoing monitoring is essential. If estrogen is appropriately managed (not crashed), the compound continues providing effective suppression. Long-term use at aggressive doses carries risks to bone density and lipid profiles. Most users transition to a milder AI or reduce dosing once the acute need has passed.

Side Effects & Safety

Common Side Effects

  • Severe joint pain, stiffness, and dryness (the hallmark side effect of aggressive estrogen suppression)
  • Fatigue and profound lethargy
  • Mood disturbance (depression, emotional flatness, irritability)
  • Decreased libido and sexual dysfunction
  • Hot flashes or flushing
  • Headache
  • Muscle aches and generalized pain

Stop Signs - Discontinue if:

  • Severe joint pain or inability to perform normal physical activities (suggests critically low estrogen)
  • Persistent depression, emotional numbness, or suicidal ideation
  • Signs of bone fracture with minimal trauma
  • Cardiovascular symptoms (chest pain, shortness of breath, leg swelling)
  • Significant liver dysfunction (jaundice, dark urine, persistent nausea)
  • Prolonged loss of libido and sexual function unresponsive to dose reduction

Contraindications

  • Known hypersensitivity to letrozole or any excipients
  • Premenopausal women (unless under specialist care for fertility treatment)
  • Pregnancy or breastfeeding (teratogenic risk -- letrozole is Category X)
  • Severe hepatic impairment
  • Pre-existing severe osteoporosis or high fracture risk
  • History of estrogen-crash-related adverse events with prior AI use

Quality Checklist

Good Signs

  • Yellow to off-white crystalline powder or uniform tablets
  • Third-party certificate of analysis (COA) confirming identity and purity (>98%)
  • HPLC or mass spectrometry testing verifying letrozole content and absence of contaminants
  • Professional packaging with batch number, expiration date, and proper labeling
  • Sourced from a licensed pharmacy, compounding pharmacy, or reputable research supplier
  • Standard 2.5mg tablets with scoring for splitting

Warning Signs

  • No COA or third-party testing available
  • Tablets are inconsistent in size, color, or hardness
  • Product labeled generically without specific compound identification
  • Packaging lacks batch number or expiration date

Bad Signs

  • Discolored, crumbling, or visibly degraded tablets
  • Unusual chemical odor or taste
  • No labeling, batch information, or expiration date
  • COA shows significant impurities or incorrect compound identity
  • Sourced from unverified vendors with no quality documentation

References

  • A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer (MA.17 trial)
    Goss PE, Ingle JN, Martino S, et al.
    New England Journal of Medicine (2003)

    Landmark randomized trial of 5,187 postmenopausal women demonstrating that letrozole 2.5mg daily after five years of tamoxifen significantly improved disease-free survival compared to placebo. Established the role of extended adjuvant AI therapy and confirmed letrozole's efficacy and tolerability profile over long-term use.

  • Letrozole, gonadotropin, or clomiphene for unexplained infertility (AMIGOS trial)
    Diamond MP, Legro RS, Coutifaris C, et al.
    New England Journal of Medicine (2015)

    Multicenter randomized trial comparing letrozole, gonadotropins, and clomiphene for ovulation induction in unexplained infertility. Demonstrated that letrozole produced comparable cumulative live birth rates with lower multiple pregnancy rates, supporting its use as a first-line fertility agent.

  • Letrozole versus clomiphene for infertility in the polycystic ovary syndrome
    Legro RS, Brzyski RG, Diamond MP, et al.
    New England Journal of Medicine (2014)

    Large multicenter trial of 750 women with PCOS showing letrozole was superior to clomiphene for ovulation induction, with higher live birth rates (27.5% vs 19.1%), higher ovulation rates, and fewer multiple gestations. Established letrozole as a preferred first-line agent for PCOS-related infertility.

  • Comparison of letrozole with tamoxifen as first-line therapy in postmenopausal breast cancer (BIG 1-98 trial)
    Thurlimann B, Keshaviah A, Coates AS, et al.
    New England Journal of Medicine (2005)

    Pivotal trial of 8,010 postmenopausal women comparing letrozole 2.5mg daily to tamoxifen 20mg daily as initial adjuvant therapy. Letrozole significantly improved disease-free survival compared to tamoxifen, with fewer thromboembolic events and less endometrial pathology. Confirmed letrozole as a first-line option superior to tamoxifen for hormone receptor-positive breast cancer.

  • Aromatase inhibitors in the treatment of breast cancer
    Lonning PE
    Steroids (2003)

    Comprehensive pharmacological review comparing the three aromatase inhibitors. Established that letrozole achieves greater than 99% aromatase inhibition in vivo, the highest of any available AI, with corresponding estradiol suppression of approximately 98%. Detailed the competitive, reversible binding mechanism and the pharmacokinetic differences between letrozole, anastrozole, and exemestane.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.